C4 therapeutics announces first patient dosed in phase 1/2 clinical trial evaluating cft7455, an orally bioavailable monodac for hematologic malignancies

– cft7455 is company's first program to advance to clinic – – cft7455 is company's first program to advance to clinic –

CCCC Ratings Summary

CCCC Quant Ranking